Beyond Ozempic: What Comes Next for Weight-Loss Drugs?
As GLP-1s conquer the scale, a new class of drugs aims to solve their biggest liability: the loss of lean tissue.
For years, the question in obesity medicine was whether a drug could produce substantial, sustained weight loss. Wegovy and Zepbound changed that conversation.
In major trials, people taking weekly injectable semaglutide, sold as Wegovy, lost an average of 14.9% of their body weight over 68 weeks. Those taking the highest dose of tirzepatide, sold as Zepbound, lost an average of 20.9% over 72 weeks. While these figures established a new efficacy benchmark, they also set the stage for a far more complex strategic challenge.
Drugmakers are now pursuing several different answers to a harder question: How can obesity treatment work better for people over the long term? The new frontiers of competition include oral formulations, multi-hormonal mechanisms of action, extended-duration injectables, and therapies designed to preserve lean muscle mass during catabolic states. These are not just incremental improvements; they represent distinct strategic bets on what patients, payers, and physicians will value most in a crowded market.
The pill is already here
The convenience of a daily pill has long been the holy grail for metabolic drug development, and it is now a tangible battleground. While weekly injections have proven commercially viable, an oral option is poised to unlock a significant market segment averse to needles. This shift is materializing in late-stage pipelines. Novo Nordisk's oral semaglutide is already approved for type 2 diabetes and is being investigated for weight management, while Eli Lilly's orforglipron, a novel small molecule GLP-1 agonist, has shown significant weight loss in its Phase 3 trials.
However, an oral route of administration does not automatically resolve the core challenges of incretin-based therapies. Orforglipron’s adverse-event profile appears consistent with the injectable GLP-1 class, meaning gastrointestinal side effects remain a critical factor for patient adherence and long-term tolerability. The arrival of oral medicines provides a crucial expansion of patient choice, but it does not erase fundamental questions about managing side effects or ensuring persistence over a multi-year treatment horizon.
Can targeting more hormones improve results?
Another key strategic vector is the escalation of biological targeting. Tirzepatide's dual-agonist mechanism, which activates receptors for both GLP-1 and GIP, provided the first major validation for moving beyond a single hormonal pathway. Eli Lilly is doubling down on this strategy with its investigational asset, retatrutide, which adds a third target: the glucagon receptor. Early data from the Phase 3 TRIUMPH-1 trial is compelling, with the highest dose yielding an average 28.3% body weight loss over 80 weeks. While retatrutide's full profile is still under investigation, it signals a clear corporate strategy to achieve unparalleled efficacy.
Novo Nordisk is pursuing a differentiated combination with zenagamtide (formerly amycretin), which co-activates GLP-1 and amylin receptors. Developed in both oral and injectable forms, its clinical program illustrates that the next wave of innovation is not monolithic. The critical question for investors and clinicians is whether these novel combinations offer a meaningfully superior risk-benefit profile, as head-to-head comparisons will be the ultimate arbiter of market share.
Redefining Adherence: The Push for Less Frequent Dosing
Efficacy in a controlled trial is one thing; real-world adherence over many years is another. This commercial reality is driving the development of less frequently administered treatments. Amgen is making a significant play in this arena with maridebart cafraglutide (MariTide), which is being tested as a monthly, or even less frequent, injection. A published Phase 2 study demonstrated substantial and sustained weight reduction with once-monthly dosing over 52 weeks, a potential game-changer for patient convenience.
The strategic importance of dosing frequency cannot be overstated. Data from the STEP 1 trial follow-up for semaglutide showed that participants regained, on average, two-thirds of their lost weight within a year of ceasing treatment. This finding underscores that obesity is a chronic condition requiring long-term management, making asset differentiation on the basis of adherence a critical commercial objective.
Weight loss is not the only outcome
Researchers are also asking what kind of weight patients lose. Weight reduction can include both fat and lean tissue. Scholar Rock has tested apitegromab alongside tirzepatide in a Phase 2 study designed to examine lean-mass preservation. The company reported less lean-mass loss with the combination than with tirzepatide alone. These are early results: preserving lean mass on a scan does not, by itself, prove that patients become stronger or have better long-term health outcomes.
Together, these programs point toward a more varied future for obesity care. Some patients may value a pill; others may benefit from a different hormone combination, fewer injections, or a treatment strategy that better supports physical function. The largest weight-loss percentage will draw attention, but the more useful measure of progress may be whether patients can access a treatment, tolerate it, maintain its benefits, and improve their health over time.
Read more about the impact of federal research funding cuts on the future of medicine and learn about the most anticipated drug launches of 2025.
Further Reading:
If you liked this article:
Share this article with your network on LinkedIn with your thoughts or perspectives. Make sure to tag us @HealthcareInsights to join the conversation.
Subscribe to our free newsletter, HealthcareIn Quicktakes. You'll never miss an article, and will get access to exclusive reports.
Check out our library of articles and reports on biotech, healthcare, policy, and business.
Who We Are: At Healthcare Insights, we're covering the transformation of healthcare and bringing our readers the most pertinent takes on key issues in medicine, biotech, healthcare policy, and business. Our Spotlight Series ✦ features thoughts from the most influential figures in healthcare, including Nobel Prize-winning scientists shaping tomorrow's treatments and business leaders bringing new therapies to market. We strive to publish coverage that is authentic, impartial, and independent of any financial or political motive. For more information regarding our editorial standards, read our statement. If you'd like to contact the Editor, use this form to get in touch.
If you'd like to stay in the loop, make sure to subscribe to our free newsletter, HealthcareIn Quicktakes, and follow us @healthcareinsights across our social channels, including LinkedIn.
©️ Copyright 2026 Healthcare Insights
All Rights Reserved
